Drug Trial Radar · NCT05516979
A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment
Last checked: Nov 19, 2026Latest source record: Nov 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Sep 26, 2022
Primary completion
Jul 20, 2023
Study completion Jul 20, 2023
Sponsor
- Lead sponsor
- SynAct Pharma ApsIndustry
- Sponsor type
- Industry
- Collaborators
- NBCD A/S
- First posted
- Aug 26, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate (MTX).
Conditions
- Rheumatoid Arthritis
Interventions
100 mg AP1189Drug
AP1189 tablets for oral use
PlaceboDrug
Matching placebo for oral use
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of reported AEsTime frame: 12 weeks
- Change in ACR20Time frame: 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Timofei Mosneaga Republican Clinical Hospital
Chisinau, Moldova
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.